FREMONT, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a
clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its
proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that it will host a conference call and
webcast to be held on Tuesday, May 15, 2018 at 4:30PM ET. At this time, management will discuss results for the first quarter of
2018 and provide an operational update. The Company will announce its financial results for this period in a press release to be
issued prior to the call.
To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at
http://ir.zosanopharma.com/events.cfm. Alternatively, you may access the live conference call by dialing (844) 379-5311 (U.S.) or
(209) 905-5963 (international). The conference ID number is 8091726.
A replay will be available on the company’s website approximately three hours after the call and available through June 15,
2018.
About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of
therapeutics to patients using our proprietary ADAM technology. The Company previously announced positive results from our
ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an
acute treatment for migraine, and is currently conducting a long-term safety study of M207. Zosano is focused on developing
products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit
to patients, for markets where patients remain underserved by existing therapies. The Company anticipates that its current and
future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and
accelerate the path towards commercialization. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the timing of expected clinical development milestones,
sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to
consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are
safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other
risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K.
Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way
guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking
statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and
Zosano assumes no obligation to update any such forward-looking statements.
Zosano Contact:
John Walker
Chief Executive Officer and Chairman of the Board
510-745-1200
